This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Mylan Inc.

Drug Names(s): CR 2249, XY2401

Description: Neboglamine is a positive allosteric glycine-site specific modulator of the glutamate N-methyl-d-aspartate (NMDA) receptor complex.

Deal Structure: Rottapharm & Xytis
In March 2005, Rottapharm S.p.A. and Xytis Pharmaceuticals Ltd announced they have signed an agreement regarding the development and commercialisation of neboglamin. Xytis has acquired an exclusive license to develop and market the compound in the United States, Canada, Japan, Australia and New Zealand, while Rottapharm retains rights in the rest of the world. The companies have not disclosed further terms of the agreement.

In January 2006, Xytis Pharmaceuticals Ltd and Remergent merged to form Xytis.

In August 2007, Rottapharm completed its acquisition of Madaus Pharma, the pharmaceutical division of Madaus Holding. The Company is now called Rottapharm Madaus.

Xytis does not appear to be in business as of November 2010. The company's phone number and website are disabled. Per a Rottapharm Madaus representative, the Company has resumed worldwide development of neboglamine.

Meda & Rottapharm
In July 2014, Meda...See full deal structure in Biomedtracker

Neboglamine News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug